Israel’s Health Ministry announced a national clinical trial that will administer MDMA and psilocybin — two psychedelic compounds long confined to the research margins — in combination with psychotherapy for patients with chronic, treatment-resistant post-traumatic stress disorder. The trial marks the most ambitious government-backed psychedelic therapy program yet attempted anywhere in the world, arriving as Israel confronts a mental health crisis of historic proportions — and as the compounds’ global regulatory trajectory turns on whether a large-scale, population-diverse trial can generate the evidence U.S. and European regulators say they still need.

Nation Under Trauma: 580,000 Israelis With Severe PTSD Symptoms

Three years after the October 7, 2023 Hamas-led attacks — in which militants killed approximately 1,200 people and took 251 hostages, triggering a multi-front war — Israel’s mental health infrastructure is under extraordinary strain. A State Comptroller report released in 2025 found that roughly 3 million adults among Israel’s population of 9.7 million had experienced anxiety, depression, or symptoms of PTSD. An estimated 580,000 people suffered severe PTSD symptoms as a direct consequence of the attacks and subsequent conflict. PTSD diagnoses rose by 70 percent in total in the year following October 7, 2023, and calls to mental health helplines increased sixfold over the same period.

The military dimension compounds the picture. A parliamentary committee found that 279 soldiers attempted suicide since 2024, a sharp increase from prior years. Israel’s second-largest healthcare provider, Maccabi, reported in its 2025 annual report that 39 percent of military personnel under its treatment had sought mental health support, and that PTSD cases among Israeli soldiers had risen 40 percent since 2023.

State Comptroller Englman said in that report: “The mental health system, which had difficulty functioning even before October 7, collapsed in the first days of the war.”

Israel’s health minister had already acknowledged the structural inadequacy, calling for a “quantum leap” in mental health provision and authorizing NIS 1.4 billion for mental health investment in early 2024. The national psychedelic trial represents a further step in that direction — one that reaches for tools far outside conventional psychiatric practice.

Why MDMA and Psilocybin: Two Distinct Mechanisms, One Treatment Gap

The rationale for MDMA and psilocybin in treatment-resistant PTSD has accumulated in peer-reviewed literature for nearly a decade. The two compounds act through different mechanisms, but both appear to create a therapeutic window that conventional pharmacology has struggled to open for the subset of PTSD patients — estimated at 30 to 40 percent — who do not respond adequately to first-line SSRIs and trauma-focused therapies.

MDMA — 3,4-methylenedioxymethamphetamine — floods the central nervous system with serotonin, oxytocin, and norepinephrine simultaneously, producing states of heightened empathy, reduced fear response, and emotional openness that allow patients to revisit traumatic memories without becoming overwhelmed. What researchers call the “therapeutic window” is neurobiological: MDMA suppresses amygdala reactivity to threat stimuli while enhancing the prefrontal cortex’s capacity for narrative processing, creating conditions in which trauma processing can occur that exposure-based therapies alone often cannot achieve. In Phase 3 clinical trials sponsored by the Multidisciplinary Association for Psychedelic Studies, between 67 and 71 percent of participants no longer met diagnostic criteria for PTSD after MDMA-assisted therapy, compared with around 32 percent in placebo groups. Those results, published in Nature Medicine, were described by researchers as the most striking efficacy signal seen for any PTSD treatment in two decades.

Psilocybin, the active compound in so-called magic mushrooms, operates through a different pathway — binding primarily to serotonin 5-HT2A receptors and temporarily disrupting the default mode network, the self-referential processing system implicated in the rigid, ruminative cognition characteristic of chronic PTSD. This produces what researchers call a state of increased neuroplasticity and cognitive flexibility that appears to loosen maladaptive patterns. A July 2026 pilot trial from Ohio State University — the first U.S. clinical study of psilocybin specifically in veterans with treatment-resistant PTSD — found that nine of twelve veterans in remission from PTSD one month after an 11-week protocol combining preparatory psychotherapy with two supervised psilocybin sessions and integration therapy. That 75 percent remission rate came with no serious adverse events. Notably, PTSD symptoms began declining during the preparatory phase, before any psilocybin was administered — a finding researchers interpreted as evidence that the drug and therapy interact synergistically rather than the compound acting alone.

A narrative clinical review published in the Journal of Clinical Medicine in August 2026, synthesizing four major studies from 2025-2026, concluded that psilocybin-assisted therapy had progressed from proof-of-concept work to a substantially expanded evidence base, while cautioning that uncertainties remain around long-term efficacy and generalizability across diverse populations.

“MDMA reduces fear and emotional reactivity, allowing patients to process traumatic memories more effectively and achieve more durable improvement,” said Dr. Revital Amiaz, Head of Psychiatry at Sheba Medical Center and a key figure in prior MDMA research in Israel.

Architecture of National Trial: Hospital Pharmacy Dispensing and Multi-Compound Protocol

The national trial announced Sunday is the broadest institutional commitment Israel has yet made to psychedelic-assisted therapy. It will enroll hundreds of patients with moderate-to-severe chronic PTSD who have not responded adequately to conventional treatment — psychotherapy modalities including prolonged exposure and EMDR, as well as first-line pharmacotherapy such as SSRIs.

What is notably new is both the combination of two distinct compounds within a single nationally coordinated framework, and the dispensing architecture designed to satisfy controlled substance requirements. Under the protocol, MDMA and psilocybin will be issued by hospital pharmacies directly to authorized therapists on treatment days — preventing stockpiling, ensuring chain of custody, and maintaining pharmaceutical-grade consistency throughout. Each dosing session is embedded within surrounding preparatory psychotherapy sessions before drug administration and integration sessions afterward — consistent with the treatment architecture validated in the MAPS Phase 3 studies.

The institutional structure addresses concerns that have accompanied psychedelic therapy in less regulated settings, including documented cases of therapist misconduct at unstructured U.S. ketamine and MDMA-adjacent practices. By routing all dispensing through hospital pharmacies and requiring institutional therapist oversight, the trial places these compounds within the same controlled-substance infrastructure that governs other scheduled medicines.

Keren Tzarfaty, MAPS Israel’s CEO described the announcement as “a concrete move toward evidence-based regulation — a shift from the exceptional-access framework of the compassionate use era toward a durable policy infrastructure grounded in prospective clinical data.”

The trial builds on an existing ecosystem of Israeli research infrastructure. Sheba Medical Center — ranked among the world’s top hospitals by Newsweek — has served as clinical sponsor for the MAPS Israel Healing October 7 initiative, a multicenter study evaluating group versus individual MDMA-assisted therapy for 168 PTSD patients diagnosed in the context of collective trauma, with participants enrolled from Nova music festival survivors, border community residents, and combat veterans across sites at Lev Hasharon Mental Health Centre and Be’er Sheva Mental Health Centre.

After FDA Rejection, Israel Steps Into Evidence Gap

Israel’s national trial arrives at a moment of significant turbulence in the global regulatory landscape — and positions the country directly in the path of the evidence gap regulators say the field needs to fill.

The FDA rejected MDMA-assisted therapy for PTSD in August 2024, citing concerns about functional unblinding, trial design limitations, and questions about demographic generalizability. The FDA’s advisory committee had voted 9-2 against recommending approval two months earlier, a result that surprised many in the field. The FDA called for an additional Phase 3 trial addressing those limitations before it would accept a resubmission. Australia remains the only country to have formally approved MDMA-assisted therapy as a prescription treatment — the Therapeutic Goods Administration rescheduled MDMA for PTSD in July 2023.

What makes Israel’s trial specifically relevant to the FDA’s stated objections is the nature of its enrolled population. The MAPS Phase 3 trials, which the FDA found demographically limited, enrolled predominantly white, educated, North American participants with individual trauma histories. Israel’s national trial will enroll patients from a collective-trauma population — encompassing combat veterans, hostage families, civilian mass-casualty survivors from the Nova festival, and border community evacuees — with documented comorbidities across a range of PTSD subtypes. That is precisely the population diversity the FDA said it needed to see.

“If our evidence convinces the regulators, I’m sure they will find a way to do it in Israel,” MAPS Israel co-founder Eyal Gura said earlier this year, framing the national trial as a matter of urgency given the scale of post-October 7 trauma. Gura had spent two years prior to Sunday’s announcement building the group therapy protocols, clinical partnerships, and trained therapist networks that the new trial depends upon.

Israel has not been a passive observer of the psychedelic research arc. It was the first country in the world to sanction a compassionate MDMA access program for PTSD, in 2019, allowing dozens of patients with treatment-resistant PTSD to undergo MDMA-assisted therapy outside formal clinical trials. That program built the therapist training base, regulatory familiarity, and institutional experience that now underpins the scale-up to a national trial.

What Comes Next: From Trial to Potential Approval Pathway

The national trial does not resolve regulatory uncertainty surrounding psychedelic-assisted therapy — it is designed to contribute to the evidence base that eventually might. Whether Israel will move from a national clinical trial to a national approval pathway for MDMA or psilocybin as registered medicines depends on the data the trial generates, the political durability of the initiative across government terms, and the trajectory of international regulatory precedent from the FDA and European Medicines Agency.

Psilocybin is at an even earlier global regulatory stage, with no major jurisdiction having approved it as a prescription medicine, though Oregon’s state-level regulated psilocybin access program and a growing number of clinical trials in the U.S., U.K., and continental Europe are generating a rapidly expanding evidence base.

What Sunday’s announcement does immediately accomplish is normalization. A national clinical trial, backed by the Health Ministry, administered through hospital pharmacy infrastructure, and conducted across multiple sites within a functioning public health system is a categorically different institutional signal than a compassionate-use exception or an isolated academic study. It places psychedelic-assisted therapy firmly within the mainstream of Israeli clinical medicine — and, given Israel’s record as a first mover in MDMA therapeutic access, it is likely to be watched by regulators and researchers in every country where PTSD treatment gaps have proved similarly intractable.

The combination of both agents within a single national trial framework also raises research questions the field has not yet systematically addressed: whether sequential or combined use of the two compounds produces additive therapeutic benefit, whether specific patient profiles respond better to one agent than the other, and what scale of clinical workforce training a national program requires. Israel’s trial may generate answers — particularly given its scope, the depth of the affected population, and the government mandate that will sustain it over several years.

For the tens of thousands of Israelis — veterans, hostage families, Nova survivors, evacuees from border communities — for whom conventional treatment has not been enough, the trial represents something more immediate than a regulatory milestone: an opening of access to therapies that, based on the evidence so far, offer a plausible chance of relief for people who have run out of conventional options.

Frequently Asked Questions

Why did the FDA reject MDMA therapy for PTSD, and how does Israel’s trial address that rejection?

The FDA issued a Complete Response Letter to MAPS/Lykos Therapeutics in August 2024, citing three primary concerns: functional unblinding (most participants correctly identified whether they received MDMA or placebo, potentially inflating self-reported outcomes), trial design limitations, and demographic homogeneity (the MAPS Phase 3 trials skewed heavily toward white, educated North American participants). Israel’s national trial will enroll a fundamentally different population — combat veterans, hostage family members, civilian mass-casualty survivors, and border community evacuees from the October 7, 2023 conflict — providing exactly the population diversity the FDA said was missing. The trial is not designed to resolve the blinding challenge, but its population data may directly address the generalizability objection the FDA raised.

How does MDMA actually work in PTSD treatment, and is it the same as recreational ecstasy?

MDMA — the same molecule found in street ecstasy — releases serotonin, oxytocin, and norepinephrine simultaneously from neurons in the central nervous system. In a clinical setting, this combination temporarily suppresses the amygdala’s threat-response reactivity while enhancing the prefrontal cortex’s capacity for narrative and emotional processing, creating a neurobiological window in which patients can approach traumatic memories without becoming acutely dysregulated. This is distinct from how SSRIs work (gradual serotonin reuptake inhibition over weeks) and from conventional exposure therapy (no pharmacological augmentation). Pharmaceutical-grade MDMA used in clinical trials is synthesized under controlled conditions and is chemically distinct in purity from street product, though the underlying molecule is the same.

Is Israel the only country running a national psychedelic PTSD trial?

Israel is currently the only country to have launched a nationally authorized clinical trial of combined MDMA and psilocybin for PTSD under government Health Ministry sponsorship, with controlled dispensing through hospital pharmacies. Australia is the only country to have fully approved MDMA therapy as a prescription treatment (since July 2023), but has not launched an equivalent national trial. The United States has multiple ongoing clinical trials under FDA investigational new drug status, but no national program — and the FDA rejected the most advanced application in August 2024. Oregon has a state-level regulated psilocybin access program (not prescription approval), and several European countries are supporting early-stage trials. Israel’s program is unique in combining both compounds, government mandate, and a hospital-integrated dispensing infrastructure at national scale.

What happens to Israelis in the trial if conventional therapy has already failed them?

Enrollment in the national trial is expected to target patients with moderate-to-severe chronic PTSD who have not responded adequately to standard first-line treatments: SSRIs (typically sertraline or paroxetine), and evidence-based psychotherapies such as prolonged exposure, cognitive processing therapy, or EMDR. For this treatment-resistant population, options in standard clinical practice are currently limited to medication augmentation strategies with limited evidence bases or escalation to intensive inpatient trauma programs. The trial offers access to a structured protocol — preparatory psychotherapy, a drug-assisted session dispensed through the hospital pharmacy, and integration therapy — that Phase 3 evidence suggests produces remission in 67-75 percent of similar patients. Participation requires referral through the national clinical infrastructure; the trial is not open self-enrollment.